Cargando…

Editorial: T-cell directed therapies in multiple myeloma

Detalles Bibliográficos
Autores principales:	Richter, Joshua, Anderson, Larry D., Ramasamy, Karthik, Rossi, Adriana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313189/ https://www.ncbi.nlm.nih.gov/pubmed/37397395 http://dx.doi.org/10.3389/fonc.2023.1206475

Ejemplares similares

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy
por: Schinke, Carolina, et al.
Publicado: (2023)

Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care
por: Seesaghur, Anouchka, et al.
Publicado: (2021)

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
por: Rodríguez-Lobato, Luis Gerardo, et al.
Publicado: (2020)

Editorial: Understanding the RNA Species in the Extracellular Vesicles of Multiple Myeloma
por: Chen, Maoshan, et al.
Publicado: (2022)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

Current Role of Radiation Therapy for Multiple Myeloma
por: Talamo, Giampaolo, et al.
Publicado: (2015)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Editorial: Risk factors in multiple myeloma identified before and during treatment: are we ready to personalize treatment?
por: D’Agostino, Mattia, et al.
Publicado: (2023)

Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches
por: van de Donk, Niels W. C. J., et al.
Publicado: (2020)

Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
por: Vu, Son Hai, et al.
Publicado: (2023)

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
por: Royle, Kara-Louise, et al.
Publicado: (2022)

Tumor Microenvironment Proteomics: Lessons From Multiple Myeloma
por: Fernando, Rodrigo Carlini, et al.
Publicado: (2021)

Local Radiation Therapy for Palliation in Patients With Multiple Myeloma of the Spine
por: Mark, Daniel, et al.
Publicado: (2019)

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Preclinical evidence of a direct pro-survival role of arginine deprivation in multiple myeloma
por: Trudu, Matteo, et al.
Publicado: (2022)

Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams
por: Pan, Darren, et al.
Publicado: (2022)

Editorial: Proteomic and metabolic reprogramming in myeloma cells within the tumor microenvironment
por: Milan, Enrico, et al.
Publicado: (2023)

Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
por: Yamamoto, Leona, et al.
Publicado: (2021)

Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy
por: Nair, Remya, et al.
Publicado: (2022)

Bispecific antibodies in multiple myeloma treatment: A journey in progress
por: Cho, Shih-Feng, et al.
Publicado: (2022)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

PIWIL1 Drives Chemoresistance in Multiple Myeloma by Modulating Mitophagy and the Myeloma Stem Cell Population
por: Wang, Yajun, et al.
Publicado: (2022)

The Role of Clonal Evolution on Progression, Blood Parameters, and Response to Therapy in Multiple Myeloma
por: Sandmann, Sarah, et al.
Publicado: (2022)

CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma
por: D'Ovidio, Tyler, et al.
Publicado: (2023)

Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells
por: Heinemann, Luca, et al.
Publicado: (2022)

Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients
por: Barilà, Gregorio, et al.
Publicado: (2021)

Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy
por: Deng, Jingjing, et al.
Publicado: (2022)

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
por: Cornell, Robert Frank, et al.
Publicado: (2019)

Pathway-Directed Therapy in Multiple Myeloma
por: John, Lukas, et al.
Publicado: (2021)

Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma
por: John, Lukas, et al.
Publicado: (2023)

An Uncommon Cause of Acute Encephalopathy in Multiple Myeloma
por: Al Zeyoudi, Jawaher, et al.
Publicado: (2021)

PET/CT in Multiple Myeloma: Beyond FDG
por: Matteucci, Federica, et al.
Publicado: (2021)

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
por: De Smedt, Eva, et al.
Publicado: (2018)

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma
por: Domenger, Antoine, et al.
Publicado: (2023)

Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment
por: Cerchione, Claudio, et al.
Publicado: (2022)

The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients
por: Yao, Weiqin, et al.
Publicado: (2023)

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
por: van der Schans, Jort J., et al.
Publicado: (2020)

Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities
por: Leblay, Noémie, et al.
Publicado: (2020)

Metabolic Reprogramming Induces Immune Cell Dysfunction in the Tumor Microenvironment of Multiple Myeloma
por: Wu, Shaojie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vj4i2qu8uge4ujngk7l9rv6gui